Article metrics

Download PDFPDF

729 A first-in-human, open-label, multicenter, phase 1/2a, dose escalation and expansion study of GI-102, a novel immunocytokine combining CD80-IL2v3, in patients with advanced or metastatic solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2023 to January 2024

AbstractFullPdf
Nov 2023218021
Dec 20237809
Jan 20244303
Total339033